Skip to Content Skip to Navigation

Over ons Praktische zaken Waar vindt u ons prof. dr. G.N. (Gert) Moll

prof. dr. G.N. (Gert) Moll

Honorary professor Protein Modification and Functionality

Geen foto beschikbaar

Faculteit Science and Engineering

Telefoon:

E-mail:

g.n.moll rug.nl

ORCID Research Portal

Publicaties

Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

Moll, G. N., 5-sep.-2024, In: European Journal of Pharmacology. 978, 8 blz., 176772.

Onderzoeksoutput › peer review

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Villela, D. C., Namsolleck, P., Reichetzeder, C. & Moll, G. N., 2023, In: Peptides. 170, 9 blz., 171106.

Onderzoeksoutput › › peer review

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

Wagenaar, G. T. M. & Moll, G. N., 15-dec.-2023, In: European Journal of Pharmacology. 961, 8 blz., 176189.

Onderzoeksoutput › peer review

Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma

Namsolleck, P., Kofler, B. & Moll, G. N., 15-jun.-2023, In: International Journal of Molecular Sciences. 24, 12, 9 blz., 10193.

Onderzoeksoutput › › peer review

LP2, a cyclic angiotensin-(1−7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice

Namsolleck, P., de Vries, L. & Moll, G. N., feb.-2023, In: Peptides. 160, 170920.

Onderzoeksoutput › › peer review

LP2, a stable lanthipeptide derived from cAng-(1-7), exerts myeloprotective action in mice

Namsolleck, P., Rodgers, K. E., Franklin, R. & Moll, G. N., mei-2023, In: European Journal of Haematology. 110, 5, blz. 534-539 6 blz.

Onderzoeksoutput › › peer review

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake

Kuipers, A., Balaskó, M., Pétervári, E., Koller, A., Brunner, S. M., Moll, G. N. & Kofler, B., okt.-2021, In: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 18, blz. 2737–2752 16 blz.

Onderzoeksoutput › › peer review

LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study

Namsolleck, P., Richardson, A., Moll, G. N. & Mescheder, A., feb.-2021, In: Peptides. 136, 170468.

Onderzoeksoutput › › peer review

An Engineered Double Lipid II Binding Motifs-Containing Lantibiotic Displays Potent and Selective Antimicrobial Activity against Enterococcus faecium

Zhao, X., Yin, Z., Breukink, E., Moll, G. N. & Kuipers, O. P., jun.-2020, In: Antimicrobial Agents and Chemotherapy. 64, 6, 12 blz., e02050-19.

Onderzoeksoutput › › peer review

Biosynthesis of lanthionine-constrained agonists of G protein-coupled receptors

Moll, G. N., Kuipers, A., Rink, R., Bosma, T., de Vries, L. & Namsolleck, P., 14-okt.-2020, In: Biochemical Society Transactions. 48, 5, blz. 2195-2203 9 blz.

Onderzoeksoutput › peer review

Alle (66) publicaties

Pers/media

Uit RUG voortgekomen Lanthio Pharma Chemische Start-up van het Jaar

Moll, G.

24/11/2014

Pers / media: Activiteiten met een maatschappelijk belang ›

Alle (1) pers/media

Bekijk volledig onderzoeksprofiel

Volg de RUGfacebook twitter linkedin rss instagram youtube